Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference

  Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess
                            Health Care Conference

PR Newswire

CARLSBAD, Calif., May 23, 2013

CARLSBAD, Calif., May 23, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS), the leader in antisense therapeutics, today announced that
management will present a company overview at the Deutsche Bank 38^th Annual
dbAccess Health Care Conference on Thursday, May 30, 2013 at 8:40 a.m. ET in
Boston, MA.

A live audio webcast of the presentation will be available on the "Investors &
Media" section of the Company's Web site, A replay will be
available on the Isis Web site within 48 hours and will be archived for a
limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 28 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, is commercializing Isis' lead product,
KYNAMRO™, in the United States for the treatment of patients with HoFH.
Genzyme is also pursuing marketing approval of KYNAMRO in other markets.
Isis' patents provide strong and extensive protection for its drugs and
technology. Additional information about Isis is available at

Forward-Looking Statements

This press release includes forward-looking statements regarding Isis'
business and the therapeutic potential of Isis' technologies and products in
development. Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs, including the commercial potential
of KYNAMRO, is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around such drugs.
Isis' forward-looking statements also involve assumptions that, if they never
materialize or prove correct, could cause its results to differ materially
from those expressed or implied by such forward-looking statements. Although
Isis' forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors currently
known by Isis. As a result, you are cautioned not to rely on these
forward-looking statements. These and other risks concerning Isis' programs
are described in additional detail in Isis' annual report on Form 10-K for the
year ended December 31, 2012, and its most recent quarterly report on Form
10-Q, which are on file with the SEC. Copies of these and other documents are
available from the Company. In this press release, unless the context
requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis
Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.
KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals Inc.

Contact: Isis Pharmaceuticals' Contacts -- D. Wade Walke, Ph.D., Executive
Director, Corporate Communications and Investor Relations, 760-603-2741; Amy
Blackley, Ph.D., Associate Director, Corporate Communications, 760-603-2772
Press spacebar to pause and continue. Press esc to stop.